CELC Celcuity Inc.

NASDAQ
$53.35

Celcuity Inc. (CELC) is expected to report earnings on February 4, 2027, after the market close. The consensus earnings estimate is a loss of $1.34 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -20.6% since its last earnings release on November 5, 2026.

Celcuity Beat Consensus Estimates
Thursday, November 5, 2026 · 4:01 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 4
Thursday · 4:00 PM ET
Earnings Whisper
-
vs ($1.34)
Rev est $32.16M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $61.16

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Celcuity Inc.

Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic and companion diagnostic strategy.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.